Based on the initial data generated in the Phase 1b trial, we believe that pociredir has the potential to increase fetal hemoglobin to levels that could ameliorate symptoms of sickle cell disease.
Bilirubin, the byproduct of hemoprotein breakdown, particularly hemoglobin, is a critical marker in diagnosing, prognosing, and managing liver diseases. Findings indicate younger-onset type 2 ...